Label expansion for Lymphoseek

The FDA approves the use of Navidea Biopharmaceuticals' (NAVB -7.4%) radioactive imaging agent Lymphoseek for use in sentinel lymph node biopsies. Sentinel lymph nodes are those closest to a primary tumor for cancer. This new indication allows for more limited lymph node surgery in patients with sentinel nodes negative for cancer.

Last year, the regulator cleared the product as an aide in the identification of lymph nodes closest to a primary tumor in patients with breast cancer or melanoma.

From other sites
Comments (3)
  • Managing
    , contributor
    Comments (314) | Send Message
    We get a positive outcome from the regulator and the stock tanks by almost <8%>? Shorts must be selling heavy.
    13 Jun 2014, 01:21 PM Reply Like
  • joelkatz
    , contributor
    Comments (570) | Send Message
    Nothing to cry, will rise in future together with its revenue
    13 Jun 2014, 01:34 PM Reply Like
  • Managing
    , contributor
    Comments (314) | Send Message
    The sell off makes no sense.
    14 Jun 2014, 04:47 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs